Interius BioTherapeutics, founded on innovations from Dr. Saar Gill's laboratory at the University of Pennsylvania, is an early-stage biotechnology company focused on revolutionizing cell and gene therapy. The company aims to develop next-generation delivery technologies that enable in vivo engineering of cells directly within the human body. Their core mission is to enhance the precision and efficacy of gene delivery, targeting the right cells with the right payloads to treat specific diseases.

Notably affiliated with the University of Pennsylvania, Interius has attracted significant attention from the biotech community. While specific investors are not listed, the company's groundbreaking approach has already positioned it as a promising player in the field. Key achievements include the development of proprietary technologies that could transform therapeutic practices. Interius BioTherapeutics is poised to make a substantial impact by potentially increasing the accessibility and effectiveness of cell and gene therapies.